Magnesium intake, mg/day | Controls, N | Deficiency | Insufficiency | ||
---|---|---|---|---|---|
N | OR (95% CI) | N | OR (95% CI) | ||
Vitamin D intake <308 (IU/day) | |||||
Q1 <225 | 1,359 | 834 | 1.00 | 1,218 | 1.00 |
Q2 225 to 310 | 940 | 328 | 0.79 (0.58 to 1.07) | 650 | 0.89 (0.69 to 1.15) |
Q3 311 to 419 | 697 | 184 | 0.64 (0.46 to 0.91) | 426 | 0.78 (0.63 to 1.08) |
Q4 ≥420 | 485 | 105 | 0.58 (0.35 to 0.97) | 242 | 0.71 (0.47 to 1.07) |
P for trend | Â | Â | 0.01 | Â | <0.05 |
Vitamin D intake ≥308 (IU/day) | |||||
Q1 <225 | 390 | 42 | 1.00 | 144 | 1.00 |
Q2 225 to 310 | 793 | 64 | 1.09 (0.47 to 2.55) | 257 | 0.94 (0.62 to 1.42) |
Q3 311 to 419 | 1,040 | 61 | 0.76 (0.30 to 1.88) | 332 | 1.19 (0.80 to 1.77) |
Q4 ≥420 | 1,258 | 57 | 0.71 (0.24 to 2.11) | 351 | 0.96 (0.60 to 1.55) |
P for trend | Â | Â | 0.97 | Â | 0.67 |
P for interaction | Â | Â | <0.001 | Â | <0.001 |
Non-vitamin D supplement user | |||||
Q1 <225 | 1,292 | 812 | 1.00 | 1,160 | 1.00 |
Q2 225 to 310 | 958 | 332 | 0.81 (0.57 to 1.14) | 651 | 0.91 (0.70 to 1.18) |
Q3 311 to 419 | 793 | 205 | 0.59 (0.40 to 0.88) | 462 | 0.80 (0.63 to 1.02) |
Q4 ≥420 | 661 | 124 | 0.60 (0.35 to 1.00) | 329 | 0.81 (0.55 to 1.19) |
P for trend | Â | Â | 0.02 | Â | 0.18 |
Vitamin D supplement user | |||||
Q1 <225 | 457 | 64 | 1.00 | 202 | 1.00 |
Q2 225 to 310 | 775 | 60 | 1.23 (0.59 to 2.56) | 256 | 0.80 (0.53 to 1.20) |
Q3 311 to 419 | 944 | 40 | 1.05 (0.41 to 1.68) | 296 | 0.96 (0.65 to 1.41) |
Q4 ≥420 | 1,082 | 38 | 0.91 (0.35 to 2.36) | 264 | 0.73 (0.49 to 1.10) |
P for trend | Â | Â | 0.56 | Â | 0.40 |
P for interaction | Â | Â | 0.47 | Â | 0.37 |
Winter and Southern latitude | |||||
Q1 <225 | 664 | 493 | 1.00 | 726 | 1.00 |
Q2 225 to 310 | 691 | 239 | 0.63 (0.47 to 0.85) | 495 | 0.73 (0.57 to 0.92) |
Q3 311 to 419 | 653 | 156 | 0.49 (0.30 to 0.78) | 422 | 0.89 (0.74 to 1.07) |
Q4 ≥420 | 680 | 111 | 0.54 (0.28 to 1.02) | 337 | 0.57 (0.41 to 0.78) |
P for trend | Â | Â | 0.03 | Â | <0.01 |
Summer and Northern latitude | |||||
Q1 <225 | 1,085 | 383 | 1.00 | 636 | 1.00 |
Q2 225 to 310 | 1,042 | 153 | 0.95 (0.64 to 1.41) | 412 | 0.91 (0.66 to 1.26) |
Q3 311 to 419 | 1,084 | 89 | 0.61 (0.43 to 0.86) | 336 | 0.73 (0.56 to 0.96) |
Q4 ≥420 | 1,063 | 51 | 0.33 (0.20 to 0.55) | 256 | 0.85 (0.61 to 1.19) |
P for trend | Â | Â | 0.001 | Â | 0.35 |
P for interaction | Â | Â | 0.55 | Â | 0.21 |
Age <50 (years) | |||||
Q1 <225 | 862 | 465 | 1.00 | 726 | 1.00 |
Q2 225 to 310 | 821 | 209 | 0.74 (0.49 to 1.11) | 495 | 0.83 (0.60 to 1.16) |
Q3 311 to 419 | 831 | 150 | 0.63 (0.35 to 1.13) | 422 | 0.84 (0.62 to 1.13) |
Q4 ≥420 | 892 | 110 | 0.67 (0.32 to 1.42) | 337 | 0.73 (0.50 to 1.08) |
P for trend | Â | Â | 0.26 | Â | 0.15 |
Age ≥50 (years) | |||||
Q1 <225 | 1,085 | 383 | 1.00 | 636 | 1.00 |
Q2 225 to 310 | 1,042 | 153 | 0.85 (0.50 to 1.37) | 412 | 0.86 (0.63 to 1.16) |
Q3 311 to 419 | 1,084 | 89 | 0.43 (0.24 to 0.77) | 336 | 0.79 (0.57 to 1.10) |
Q4 ≥420 | 1,063 | 51 | 0.24 (0.11 to 0.49) | 256 | 0.71 (0.46 to 1.10) |
P for trend | Â | Â | <0.01 | Â | 0.81 |
P for interaction | Â | Â | 0.07 | Â | 0.41 |
Male | |||||
Q1 <225 | 712 | 283 | 1.00 | 519 | 1.00 |
Q2 225 to 310 | 854 | 164 | 0.64 (0.41 to 1.00) | 466 | 1.12 (0.78 to 1.61) |
Q3 311 to 419 | 995 | 143 | 0.39 (0.21 to 0.74) | 439 | 0.90 (0.65 to 1.26) |
Q4 ≥420 | 1,150 | 106 | 0.33 (0.16 to 0.69) | 409 | 0.95 (0.59 to 1.52) |
P for trend | Â | Â | 0.001 | Â | 0.54 |
Female | |||||
Q1 <225 | 1,037 | 593 | 1.00 | 843 | 1.00 |
Q2 225 to 310 | 879 | 228 | 0.85 (0.61 to 1.21) | 441 | 0.71 (0.54 to 0.93) |
Q3 311 to 419 | 742 | 102 | 0.63 (0.37 to 1.05) | 319 | 0.83 (0.64 to 1.07) |
Q4 ≥420 | 593 | 56 | 0.47 (0.25 to 0.87) | 184 | 0.60 (0.43 to 0.82) |
P for trend | Â | Â | 0.16 | Â | 0.14 |
P for interaction | Â | Â | 0.11 | Â | 0.17 |
Non-Hispanic Black | |||||
Q1 <225 | 181 | 530 | 1.00 | 442 | 1.00 |
Q2 225 to 310 | 163 | 181 | 0.51 (0.34 to 0.76) | 229 | 0.74 (0.53 to 1.03) |
Q3 311 to 419 | 110 | 115 | 0.44 (0.26 to 0.74) | 175 | 0.53 (0.33 to 0.88) |
Q4 ≥420 | 104 | 81 | 0.43 (0.27 to 0.68) | 119 | 0.64 (0.39 to 1.04) |
P for trend | Â | Â | <0.001 | Â | <0.05 |
Non-Hispanic Caucasian and others | |||||
Q1 <225 | 1,568 | 346 | 1.00 | 920 | 1.00 |
Q2 225 to 310 | 1,570 | 212 | 0.91 (0.65 to 1.28) | 678 | 0.86 (0.67 to 1.10) |
Q3 311 to 419 | 1,627 | 130 | 0.66 (0.45 to 0.97) | 583 | 0.87 (0.67 to 1.10) |
Q4 ≥420 | 1,639 | 81 | 0.52 (0.29 to 0.95) | 474 | 0.76 (0.58 to 0.99) |
P for trend | Â | Â | <0.05 | Â | 0.27 |
P for interaction | Â | Â | 0.305 | Â | 0.82 |
BMI <25 (kg/m2) | |||||
Q1 <225 | 631 | 172 | 1.00 | 336 | 1.00 |
Q2 225 to 310 | 611 | 90 | 1.04 (0.51 to 2.12) | 339 | 0.92 (0.61 to 1.40) |
Q3 311 to 419 | 606 | 58 | 0.84 (0.40 to 1.76) | 189 | 1.00 (0.70 to 1.44) |
Q4 ≥420 | 608 | 41 | 0.51 (0.23 to 1.15) | 162 | 0.77 (0.47 to 1.27) |
P for trend | Â | Â | 0.13 | Â | 0.45 |
BMI ≥25 to <30 (kg/m2) | |||||
Q1 <225 | 605 | 232 | 1.00 | 448 | 1.00 |
Q2 225 to 310 | 632 | 106 | 0.71 (0.43 to 1.15) | 316 | 0.77 (0.51 to 1.17) |
Q3 311 to 419 | 661 | 75 | 0.50 (0.29 to 0.86) | 266 | 0.63 (0.50 to 0.79) |
Q4 ≥420 | 677 | 46 | 0.47 (0.22 to 1.01) | 213 | 0.73 (0.48 to 1.13) |
P for trend | Â | Â | 0.02 | Â | 0.06 |
BMI ≥30 (kg/m2) | |||||
Q1 <225 | 463 | 440 | 1.00 | 532 | 1.00 |
Q2 225 to 310 | 457 | 177 | 0.63 (0.35 to 1.14) | 341 | 0.82 (0.63 to 1.06) |
Q3 311 to 419 | 441 | 108 | 0.46 (0.24 to 0.88) | 288 | 0.83 (0.59 to 1.15) |
Q4 ≥420 | 424 | 69 | 0.42 (0.19 to 0.96) | 202 | 0.63 (0.44 to 0.91) |
P for trend | Â | Â | 0.02 | Â | 0.02 |
P for interaction | Â | Â | 0.23 | Â | 0.13 |
PTH <32 (pg/ml) | |||||
Q1 <225 | 322 | 63 | 1.00 | 179 | 1.00 |
Q2 225 to 310 | 369 | 39 | 0.42 (0.18 to 1.02) | 109 | 0.72 (0.42 to 1.24) |
Q3 311 to 419 | 363 | 21 | 0.17 (0.07 to 0.43) | 107 | 0.77 (0.47 to 1.28) |
Q4 ≥420 | 392 | 19 | 0.22 (0.07 to 0.73) | 100 | 0.74 (0.38 to 1.42) |
P for trend | Â | Â | <0.01 | Â | 0.46 |
PTH ≥32 to <46 (pg/ml) | |||||
Q1 <225 | 378 | 136 | 1.00 | 271 | 1.00 |
Q2 225 to 310 | 382 | 66 | 1.20 (0.66 to 2.21) | 195 | 0.94 (0.73 to 1.22) |
Q3 311 to 419 | 406 | 54 | 1.19 (0.53 to 2.66) | 181 | 0.85 (0.59 to 1.23) |
Q4 ≥420 | 414 | 33 | 1.11 (0.36 to 3.42) | 131 | 0.79 (0.55 to 1.15) |
P for trend | Â | Â | 0.85 | Â | 0.24 |
PTH ≥46 (pg/ml) | |||||
Q1 <225 | 390 | 375 | 1.00 | 447 | 1.00 |
Q2 225 to 310 | 382 | 157 | 0.73 (0.48 to 1.10) | 297 | 0.93 (0.68 to 1.28) |
Q3 311 to 419 | 382 | 95 | 0.52 (0.28 to 0.95) | 209 | 0.78 (0.60 to 1.01) |
Q4 ≥420 | 365 | 50 | 0.28 (0.14 to 0.53) | 159 | 0.57 (0.35 to 0.92) |
P for trend | Â | Â | 0.01 | Â | 0.41 |
P for interaction | Â | Â | 0.73 | Â | 0.53 |